Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Frank Douglas (Aventis) called Millennium 'a strong partner with world-class genomics capabilities'; Mark Levin (Millennium) said it was the first time…
Described the deal as 'highly advantageous' for Millennium and 'a quick and economical way' for newly-formed Aventis to fill operational gaps post-merger.
Retrospective Axial analysis noted the deal exemplified the 2000 genomics-alliance peak; Millennium funded Cambridge Discovery Chemistry acquisition with…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Aventis-Millennium 'groundbreaking' five-year alliance to discover, develop and co-market anti-inflammatory drugs. $250M equity investment (~2.5% stake) plus $200M in research fees over five years. First biotech-pharma deal on truly equal terms — 50/50 cost and US profit share.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Aventis Pharma AG / Millennium Pharmaceuticals (this deal) | 2000 | $450M | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Roche Holding AG / Genentech, Inc. (Roche Group) | 2009 | $46.8B | 72 |
| Travere Therapeutics, Inc. / Everest Medicines Limited | 2026 | $1.1B | 72 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
← Browse all deals · How we score deals
More: 2000 deals · Immunology deals